Erythropoietin Reduces Post-PCI Arrhythmias in Patients With ST-elevation Myocardial Infarction

BACKGROUND:Arrhythmia is the foremost cause of sudden death after myocardial infarction (MI). Animal models have recently shown that erythropoietin (EPO) can reduce the incidence of arrhythmia after MI. METHODS:We investigated the effects of administrating 33,000 IU EPO on the occurrence of post-MI...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of cardiovascular pharmacology 2015-06, Vol.65 (6), p.555-561
Hauptverfasser:	Gholamzadeh, Ali, Amini, Sara, Mohammadpour, Amir H, Vahabzadeh, Maryam, Fazelifar, Amir F, Fazlinezhad, Afsoon, Dehghani, Mashalla, Moohebati, Mohsen, Dastani, Mostafa, Malaekeh-Nikouie, Bizhan, Falsoleiman, Homa
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Anti-Arrhythmia Agents - administration & dosage Anti-Arrhythmia Agents - adverse effects Arrhythmias, Cardiac - diagnosis Arrhythmias, Cardiac - etiology Arrhythmias, Cardiac - physiopathology Arrhythmias, Cardiac - prevention & control Biomarkers - blood Creatine Kinase, MB Form - blood Electrocardiography Erythropoietin - administration & dosage Erythropoietin - adverse effects Female Hemodynamics - drug effects Humans Iran Male Middle Aged Myocardial Infarction - complications Myocardial Infarction - diagnosis Myocardial Infarction - physiopathology Myocardial Infarction - therapy Original Percutaneous Coronary Intervention - adverse effects Pilot Projects Platelet Aggregation Inhibitors - therapeutic use Recombinant Proteins - administration & dosage Risk Factors Time Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!